Information regarding transition of BTA to shares in Diamyd Medical
The transition of BTA 1 (SE0008014286 and SE0008014310) into shares in Diamyd Medical takes place in the end of this week. Directly registered holders are expected to receive shares on Monday, March 21, 2016. Nominee shareholders will receive shares according to respective nominee’s routines. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively